Church: CRISPR is gene damaging rather than precision editing
George Church · a16z Podcast | What's in the Water at the George Church Lab? · Apr 1, 2019 · at 3:16
Geneticist George Church clarifies how CRISPR functions in gene editing applications during a discussion with a16z partner Jorge Conde.
0:00 / 0:09exact quote · 9.3s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“So what CRISPR does well, it's often described as editing. It really is damaging, is what it is. It's not really that good at precision editing.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from George Church
Church: Chinese government likely knew about CRISPR baby experiment
“I wouldn't characterize it as a solo effort. I've seen the author list. It's quite long, and I also find it unlikely that a government as technically astute and as engaged in observation would be unaware of such an important thing.”
Church: Targeting HIV via CRISPR is more justifiable than Mendelian diseases
“Yeah, I think that we want an example of a disease that is very common, and most of the gene therapies are rare, whether they're editing or not, and we want something that's very serious, and certainly HIV falls in that category, So it struck me as a plausibly…”
Church: Off-target edits appear low in first two CRISPR babies
“So the amount of off-target and mosaicism so far for these two babies seems to be low, but time will tell.”
Church: Embryo selection avoids Mendelian diseases without CRISPR editing
“Ignoring the fact that if you're in an IVF, PGD clinic anyway. To do your CRISPR editing of your Mendelian disease, you could just do selection for most of these things.”
Church: Gene editing moratoriums will accelerate research rather than halt it
“Well, there probably will be something that looks like a pause, but it will probably be an acceleration.”
Church: Regulators favor breakthrough therapeutic platforms over incremental updates
“To some extent, I think they like new technologies more than they like the old ones. The old ones tend to fail because they're so incremental that they're no longer compared to the placebo, they're compared to whatever they're in increment over, whatever thera…”